Galway-headquartered medtech company Aerogen has announced a €300 million “scaling and investment plan” which will create 725 jobs over the next 10 years.
The Dangan-based group is one of the world’s leading manufacturers of respiratory nebulisers and is Ireland’s largest indigenous medtech firm.
The company, which has been growing at a rate of 20 per cent per annum for the last decade, said it planned to accelerate its existing device technology through “new product innovation and leveraging of global opportunities”.
News of its expansion came as Enterprise Ireland (EI) announced employment at companies supported by the agency rose to a record 234,454 last year, with 15,741 new jobs created. The jobs growth translated into a net increase of 6,212.
The domestic business support agency said 64 per cent of the new jobs created were located outside the Dublin region with all nine regions recording jobs growth.
It noted that employment increased across the agency’s three core economic sectors: technology and services (+2 per cent), industrial and life sciences (+3 per cent); and food and sustainability (+3 per cent). The total export value generated by Enterprise Ireland-supported companies stood at €34 billion a year.
Commenting on the latest figures Minister for Enterprise Peter Burke said: “It is hugely positive to see Enterprise Ireland supported companies recording job growth for the fourth year in a row.”
“2024 was a challenging year for some sectors of exporting Irish businesses with high interest rates and international instability impacting business performance, so to record significant employment growth is even more impressive,” he said, noting the Aerogen announcement “demonstrates the continued success of Irish companies’ performance in export markets”.
Aerogen, which now has annual revenues of over €150 million, said its investment plan will increase its global workforce to over 2,000 of which over 1,100 will be based in Ireland. The new jobs will be across research and development (R&D), manufacturing, science and engineering and located at its two manufacturing sites in Parkmore, Galway and in Shannon.
Aerogen’s drug delivery devices are used in the treatment of critical respiratory illness and other non-respiratory illnesses. They have been used to treat over 25 million patients in emergency departments, adult and paediatric ICUs, general wards and ambulance services.
John Power, chief executive and founder Aerogen said: “We are delighted to announce this continued expansion of Aerogen as a truly global life science company.”
“Enterprise Ireland have been a superb partner in supporting this journey on which we just reached the pivotal milestone of having treated our 25th millionth patient, and we will continue to innovate across the respiratory journey for patients from our HQ here in Galway,” he said.
- Sign up for the Business Today newsletter and get the latest business news and commentary in your inbox every weekday morning
- Opt in to Business push alerts and have the best news, analysis and comment delivered directly to your phone
- Join The Irish Times on WhatsApp and stay up to date
- Our Inside Business podcast is published weekly – Find the latest episode here
